Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
76 of 180 long COVID-associated genes also linked to ME
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
HYMPAVZI’s safety profile was generally favorable
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated